Cohen G, Rapoport B, Chan SW, Ruff P, et al. Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PLoS One 2024;19:e0309778.
PMID: 39531423